Earnings call transcript: Viveo beats Q3 2026 estimates as restructuring gains traction

Vivo, a Brazilian healthcare company, reported better-than-expected results in Q3 2026, despite facing challenges. The company posted adjusted earnings per share of -$0.0858, surpassing the expected -$0.24. Revenue reached $2.99 billion, exceeding the forecast of $2.92 billion. Net revenue grew 7.8% year-over-year to BRL 3.55 billion, driven by strong performance in hospital and clinic sales, which increased 18.9% quarter-over-quarter.

Adjusted EBITDA rose 13.1% year-over-year, with a margin of 6.4%. Free cash flow increased 51.4% to BRL 150 million. Management highlighted a successful restructuring, including a capital increase and debt reduction, which contributed to improved financial metrics. Despite a fire at the Cremer facility and other near-term pressures, Vivo demonstrated progress in cost reduction, margin improvement, and balance sheet strengthening.